<div id="readability-page-1"><p>In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se, with a price target of <span id="expert-recommendation-target">$925.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Issi is a 2-star analyst with an average return of <span>0.1%</span> and a 39.47% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, uniQure, and Ascendis Pharma.</p> <p>In addition to RBC Capital, Argenx Se also received a Buy from Wells Fargo’s Derek Archila in a report issued yesterday. However, on the same day, UBS maintained a Hold rating on Argenx Se (NASDAQ: ARGX).</p></div>

ARGX

<p>RBC Capital's Luca Issi maintains a Buy rating on Argenx Se with a $925 price target. Issi, a 2-star analyst, has a 0.1% average return and a 39.47% success rate, focusing on healthcare stocks. Wells Fargo also issued a Buy rating, while UBS maintained a Hold rating on Argenx Se.</p>

RBC Capital Keeps Their Buy Rating on Argenx Se (ARGX)